Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,122 public posts
Filter results
Actual duration of Lupron Depot 22.5 mg/12 weeks X 2.
Testoterone was below ''
Level'' from July 29th 2020 to March 10th 2021.
My PSA went from
[u]
0.18μg/L
[/u]
, July 29th 2020 down to 0.03μg/L on September 07 2022
Testoterone was below ''
Level'' from July 29th 2020 to March 10th 2021.
My PSA went from
[u]
0.18μg/L
[/u]
, July 29th 2020 down to 0.03μg/L on September 07 2022
doc1947g
in
Advanced Prostate Cancer
2 years ago
Terbium-161 instead of Lutetium-177
VIOLET: A phase I/II trial evaluation of radioligand treatment in men with metastatic
castration
-resistant prostate cancer with [161Tb]Tb-PSMA-I&T. https://meetings.asco.org/abstracts-presentations/217246
VIOLET: A phase I/II trial evaluation of radioligand treatment in men with metastatic
castration
-resistant prostate cancer with [161Tb]Tb-PSMA-I&T. https://meetings.asco.org/abstracts-presentations/217246
TeleGuy
in
Advanced Prostate Cancer
1 year ago
Advanced PC with a 90 years old
When he becomes
castration
resistant in the future, I'm afraid he won't have many options because of his age and health condition. With
castration
resistance, is ADT and another AR inhibitor or CYP17 inhibitor still a treatment option for him?
When he becomes
castration
resistant in the future, I'm afraid he won't have many options because of his age and health condition. With
castration
resistance, is ADT and another AR inhibitor or CYP17 inhibitor still a treatment option for him?
TN1932
in
Advanced Prostate Cancer
2 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Мой опыт и мои мысли о прохождении радиолигандной терапии с использованием лиганда PSMA-617, содержащего изотопы 177Lu и 225Ac. Часть 2.
Also, I was advised to continue ADT in order to keep my Testosterone at
castration
values. Let me remind you that, by that time, I had not taken any antiandrogens. Dr.
Also, I was advised to continue ADT in order to keep my Testosterone at
castration
values. Let me remind you that, by that time, I had not taken any antiandrogens. Dr.
RusLand
in
Advanced Prostate Cancer
2 years ago
Opinions on Lu-PSMA-617 Clinical Trial
Hello all, my father’s oncologist has suggested we start looking into clinical trials or chemotherapy now for his metastatic
castration
resistant prostate cancer (metastasized to the coccyx/pelvic bone in 2019). The trial the oncologist suggested is in the title.
Hello all, my father’s oncologist has suggested we start looking into clinical trials or chemotherapy now for his metastatic
castration
resistant prostate cancer (metastasized to the coccyx/pelvic bone in 2019). The trial the oncologist suggested is in the title.
PHnerd
in
Advanced Prostate Cancer
2 years ago
When is it time to discuss death with your oncologist?
He is the coordinating researcher of CAPRI (
CAstration
-resistant Prostate cancer RegIstry) https://youtu.be/wwvQXJo2aJE
He is the coordinating researcher of CAPRI (
CAstration
-resistant Prostate cancer RegIstry) https://youtu.be/wwvQXJo2aJE
Darryl
Partner
in
Advanced Prostate Cancer
2 years ago
Eliquis and Xtandi - Drug Interaction
Enzalutamide, a novel, oral androgen receptor antagonist used for the treatment of metastatic,
castration
-resistant prostate cancer, has been shown to improve overall and progression-free survival, prolong time to initiation of chemotherapy, reduce skeletal-related events, and carry a favorable adverse
Enzalutamide, a novel, oral androgen receptor antagonist used for the treatment of metastatic,
castration
-resistant prostate cancer, has been shown to improve overall and progression-free survival, prolong time to initiation of chemotherapy, reduce skeletal-related events, and carry a favorable adverse
Hawk56
in
Advanced Prostate Cancer
1 year ago
Rezvilutamide: new anti-androgen is better than Casodex added to ADT for newly diagnosed high-met HSPC. But is field too crowded?
It also significantly increased time to
castration
resistance by 79%. Like Nubeqa, Rezvilutamide doesn't appreciably penetrate the blood-brain barrier. There weren't any large differences in side effects.
It also significantly increased time to
castration
resistance by 79%. Like Nubeqa, Rezvilutamide doesn't appreciably penetrate the blood-brain barrier. There weren't any large differences in side effects.
Tall_Allen
in
Advanced Prostate Cancer
2 years ago
Long Term Zoloft/Sertraline, or other SSRI Treatment, might increase Coronary Artery Atherosclerosis and stroke risk
Nowadays, I fight mild depression (caused by cancer and
castration
meds) by exercising, listening to music I love, on good headphones, and drinking Jade Leaf Matcha green tea powder. I feel happiest after jogging with the headphone music playing.
Nowadays, I fight mild depression (caused by cancer and
castration
meds) by exercising, listening to music I love, on good headphones, and drinking Jade Leaf Matcha green tea powder. I feel happiest after jogging with the headphone music playing.
GeorgeGlass
in
Advanced Prostate Cancer
2 years ago
Would like help in treatment options.
I didn't fully realize until a visit with my urologist for a bladder cancer clean up that the
castration
sensitivity ends at some point for every one. I have been riding along thinking I could stay sensitive for years.
I didn't fully realize until a visit with my urologist for a bladder cancer clean up that the
castration
sensitivity ends at some point for every one. I have been riding along thinking I could stay sensitive for years.
agyoung
in
Advanced Prostate Cancer
2 years ago
Absolutely furious!
I did not add I am qualified in
castration
(cattle) but will be happy to use these skills on the buffoon who ordered this, with a rusty scalpel!
I did not add I am qualified in
castration
(cattle) but will be happy to use these skills on the buffoon who ordered this, with a rusty scalpel!
serenfach
in
Thyroid UK
2 years ago
Anyone prescribe Metformin for prostate cancer not for diabetes?
Docetaxel is a standard of care in metastatic
castration
-resistant prostate cancer (mCRPC), however it is still a palliative treatment with a median overall survival of ~3 years in the first line setting.
Docetaxel is a standard of care in metastatic
castration
-resistant prostate cancer (mCRPC), however it is still a palliative treatment with a median overall survival of ~3 years in the first line setting.
Shorehousejam
in
Advanced Prostate Cancer
2 years ago
PSA suppression
With Denmeade's BAT, testosterone levels are modulated - and there is no
castration
-only phase. In my original protocol, there was an abrupt shift from high-normal to castrate testosterone.
With Denmeade's BAT, testosterone levels are modulated - and there is no
castration
-only phase. In my original protocol, there was an abrupt shift from high-normal to castrate testosterone.
pca2004
in
Fight Prostate Cancer
5 months ago
New articles from the NIH
A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with
castration
-resistant prostate cancer and skeletal metastases.
A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with
castration
-resistant prostate cancer and skeletal metastases.
Magnus1964
in
Prostate Cancer Network
1 year ago
New NIH articles on prostate cancer
A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with
castration
-resistant prostate cancer and skeletal metastases.
A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with
castration
-resistant prostate cancer and skeletal metastases.
Magnus1964
in
Advanced Prostate Cancer
1 year ago
Xtandi and Talzenna
From Urotoday.com: "Pfizer Inc. announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide) compared to placebo plus XTANDI in men with metastatic
castration
-resistant prostate
From Urotoday.com: "Pfizer Inc. announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide) compared to placebo plus XTANDI in men with metastatic
castration
-resistant prostate
Bjry
in
Advanced Prostate Cancer
1 year ago
Updated trial fails to show any real benefit to metastasis-directed therapy (MDT) in oligometastatic patients
(HR=0.44) • Radiographic progression-free survival (rPFS) was not significantly different • Time to
castration
resistance was not significantly different • Overall survival was not significantly different • PFS increased by about 5-6 months regardless of whether there were high-risk mutations (BRCA
(HR=0.44) • Radiographic progression-free survival (rPFS) was not significantly different • Time to
castration
resistance was not significantly different • Overall survival was not significantly different • PFS increased by about 5-6 months regardless of whether there were high-risk mutations (BRCA
Tall_Allen
in
Advanced Prostate Cancer
2 years ago
Roche Abandons AKT Prostate Cancer Asset
Another one bites the dust ☹️ Roche Abandons AKT Prostate Cancer Asset Published: Feb 02, 2023 By Tristan Manalac Courtesy Smith Collection/Gado/Getty Images Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for
castration
-resistant
Another one bites the dust ☹️ Roche Abandons AKT Prostate Cancer Asset Published: Feb 02, 2023 By Tristan Manalac Courtesy Smith Collection/Gado/Getty Images Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for
castration
-resistant
Scout4answers
in
Advanced Prostate Cancer
1 year ago
Robust PSA Drops With Radionuclide Therapy in CRPCa— All but one patient had a PSA decline after a fractionated dose of 225Ac-J591
During his discussion, Scher said the case report "changed the metrics for patients with metastatic
castration
-resistant prostate cancer. There is no systemic therapy that has been shown to do this.
During his discussion, Scher said the case report "changed the metrics for patients with metastatic
castration
-resistant prostate cancer. There is no systemic therapy that has been shown to do this.
cujoe
in
Fight Prostate Cancer
1 year ago
FYI: from the VA research information on Veterans
Drug could delay prostate cancer spread—In 2018, the Food and Drug Administration approved the use of apalutamide for
castration
-resistant prostate cancer that has not spread to other parts of the body.
Drug could delay prostate cancer spread—In 2018, the Food and Drug Administration approved the use of apalutamide for
castration
-resistant prostate cancer that has not spread to other parts of the body.
MouseAddams
in
Advanced Prostate Cancer
7 months ago
1
...
10
11
12
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
999 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest